AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Monte Rosa Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00X2VGZR2
10.84▼ 0.27 (-2.43%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
11.11
Day's Range
10.61 – 11.03
52-Week Range
9.50 – 25.77
Volume
817.7K
Avg Volume
1.4M
Share Statistics
Shares Outstanding
Employees
150
Exchange
XNAS
Listed
2021-06-24
Share count as of July 31, 2026

Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Monte Rosa Therapeutics, Inc. Common Stock (GLUE)
What is Monte Rosa Therapeutics, Inc. Common Stock's Market Cap?
Monte Rosa Therapeutics, Inc. Common Stock's Market Cap is $924.8M, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's Enterprise Value?
Monte Rosa Therapeutics, Inc. Common Stock's Enterprise Value is $834.7M, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's Price / Sales?
Monte Rosa Therapeutics, Inc. Common Stock's Price / Sales is 32.2×, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's EV / Revenue?
Monte Rosa Therapeutics, Inc. Common Stock's EV / Revenue is 29.1×, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's EV / EBITDA?
Monte Rosa Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's Revenue (TTM)?
Monte Rosa Therapeutics, Inc. Common Stock's Revenue (TTM) is $28.7M, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's Net Income (TTM)?
Monte Rosa Therapeutics, Inc. Common Stock's Net Income (TTM) is -$161.1M, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's EBITDA?
Monte Rosa Therapeutics, Inc. Common Stock's EBITDA is -$171.1M, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Monte Rosa Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.89, based on as-reported figures from SEC (XBRL) filings.
What is Monte Rosa Therapeutics, Inc. Common Stock's EBITDA Margin?
Monte Rosa Therapeutics, Inc. Common Stock's EBITDA Margin is -595.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GLUEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration Revenue
YoY growth-61.3%-95.0%-95.4%+38.5%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue647.8%1288.5%1887.7%358.3%
(Loss) income from operations
% of revenue-547.8%-1188.5%-1787.7%-258.3%
Other income:
Interest income
Foreign currency exchange gain
Gain on disposal of property and equipment
Total other income
Net (loss) income before income taxes
Income tax provision
Net (loss) income
% of revenue-483.9%-1057.1%-1658.9%-212.1%
Comprehensive loss (income):
Provision for pension benefit obligation
Unrealized loss on available-for-sale securities——
Comprehensive (loss) income
(Loss) earnings per share:
Basic—
Diluted—